StephenLiuMD(He/Him)
Oncology • Washington, DCThoracic Cancer
Associate Professor, Georgetown University School of Medicine
Dr. Liu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3800 Reservoir Rd NW
Lombardi Comprehensive Cancer Clinic
Washington, DC 20007Phone+1 202-444-2223Fax+1 202-444-7009- Is this information wrong?
Summary
- Dr. Stephen V. Liu, MD, is an Associate Professor of Medicine, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Lombardi Comprehensive Cancer Center of Georgetown University in Washington DC, USA. He is also the host for the official IASLC podcast, Lung Cancer Considered.
Education & Training
University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2009 - 2010- University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2008 - 2009
University of Pennsylvania Health SystemResidency, Internal Medicine, 2005 - 2008
University of Maryland School of MedicineClass of 2005
Certifications & Licensure
CA State Medical License 2008 - Present
DC State Medical License 2013 - 2024
MD State Medical License 2013 - 2024
PA State Medical License 2005 - 2008- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013
Clinical Trials
- Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor Start of enrollment: 2016 May 11
- A Study of EP0031 in Patients With Advanced RET-altered Malignancies Start of enrollment: 2022 Sep 30
Roles: Contact
- A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) Start of enrollment: 2022 Jan 04
Publications & Presentations
PubMed
- 102 citationsSafety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trialAaron S. Mansfield, A. Każarnowicz, Nina Karaseva, A. Sánchez, R De Boer
Annals of Oncology. 2020-02-01 - 1863 citationsFirst-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerLeora Horn, Aaron S. Mansfield, Aleksandra Szczesna, Libor Havel, Maciej Krzakowski
The New England Journal of Medicine. 2018-09-25 - 65 citationsCharacterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer.Julia Judd, Nagla Abdel Karim, Hina Khan, Abdul Rafeh Naqash, Yasmine Baca
Molecular Cancer Therapeutics. 2021-09-13
Press Mentions
Second-Line Treatment Shortfall for Metastatic NSCLCJune 7th, 2024- Immunotherapy, Next-Generation Sequencing, and Shared Decision-Making in the Treatment of Non–Small Cell Lung CancerMay 17th, 2023
- WCLC 2022 Daily Highlights – August 9August 9th, 2022
- Join now to see all
Hospital Affiliations
MedStar Georgetown University HospitalWashington, District of Columbia
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
